ACTA ONCOLOGICA

简称 ACTA ONCOL ·NORWAY ·出版周期 Bimonthly ·年均收录 205 篇

2.2

最新影响因子

11.10%

自引率

约50%

投稿难度

平均3月

审稿周期

期刊简介

ACTA ONCOLOGICA是一本国际性的肿瘤学期刊，ISSN号为0284-186X，由Taylor & Francis出版集团出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据最新数据在肿瘤学领域处于中等水平，目前不是完全开放获取（OA）期刊，但提供混合出版模式。ACTA ONCOLOGICA被SCI收录，并且在中科院分区中通常位于医学或肿瘤学领域的3区或4区。该期刊的发文特点涵盖肿瘤学的临床与基础研究，重点关注癌症的诊断、治疗、流行病学及转化医学研究，尤其倾向于发表北欧地区的肿瘤学研究。其研究领域包括但不限于肿瘤生物学、放射治疗、化疗、免疫治疗及癌症护理。期刊质量较为稳定，审稿流程严格，但影响因子相对较低可能影响部分学者的投稿意愿。需要注意的是，由于出版模式非完全OA，部分内容可能需要订阅才能获取，这可能限制文章的传播范围。总体而言，ACTA ONCOLOGICA适合发表肿瘤学领域的中高水平研究，尤其对北欧地区的研究者较为友好。

影响因子趋势

近期发表

18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting 2024-08-12

Multi-disciplinary team meetings for lung cancer in Norway and Denmark: results from national surveys and observations with MDT-MODe 2024-08-12

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab 2024-08-12

Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study 2024-08-08

Electron beam radiotherapy for the management of squamous cell carcinoma of the anal margin 2024-08-08

Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy 2024-08-05

Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study 2024-08-05

Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis 2024-08-05

Laryngeal cancer relative survival trends from 1972 to 2021 in the Nordic countries 2024-08-05

Distressed personality is associated with late adverse effects in long-term survivors of Hodgkin lymphoma 2024-08-05